KEY TAKEAWAYS
- The study aimed to investigate the patterns and survival rates of ovarian-derived liver metastasis patients undergoing hepatic resections with or without HIPEC.
- Researchers noticed that complete cytoreductive surgery offers potential survival benefits for ovarian cancer patients.
Miklos Acs and his team aimed to assess patterns, perioperative outcomes, and survival rates of patients undergoing hepatic resections for liver metastasis from ovarian cancer as part of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Their additional objective was to examine two tumor pattern subgroups: hematogenous liver metastasis and infiltrative liver metastatic spread.
Researchers performed an inclusive analysis through a retrospective study involving patients with primary or recurrent ovarian cancer at a University Tertiary Hepatic and Peritoneal Surface Malignancy Center. The study focused on individuals who underwent liver resection during cytoreductive surgery from January 1992 to December 2022.
About 35 patients’ data underwent analysis, revealing a median overall survival (OS) and disease-specific survival (DSS) of 24.97 months. In a multivariate context, researchers tested the combined impact of age, peritoneal carcinomatosis index, body mass index, hematogenous liver metastasis vs. infiltrative spread types, and HIPEC (HR=0.2372; 95%CI=0.0719-0.7823; P=0.0181) over OS. Survival analysis indicated no significant differences between the two metastatic spread types (OS: P=0.9720; DSS: P=0.9610). Younger age (P=0.0301), splenectomy (P=0.0320), lesser omentectomy (P=0.0178), and right upper quadrant peritonectomy (P=0.0373) were more characteristic of patients with infiltrative liver metastatic spread.
The study concluded that complete cytoreductive surgery, encompassing hepatic resection with or without additional HIPEC, is a viable and beneficial approach for patients facing advanced and/or recurrent ovarian cancer. The study recommends using liver-specific imaging for improved diagnostic precision in cases where metastatic and infiltrative liver involvement is suspected.
Source: https://pubmed.ncbi.nlm.nih.gov/38307555/
Acs M, Herold Z, Neumann L, Slowik P, et al (2024). “Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center. Anticancer Res. 2024 Feb;44(2):731-741. doi: 10.21873/anticanres.16864. PMID: 38307555.
